Adaptimmune Therapeutics PLC (ADAP) Given Average Recommendation of “Hold” by Analysts
Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have been assigned a consensus recommendation of “Hold” from the eight brokerages that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $15.50.
ADAP has been the topic of a number of recent analyst reports. Zacks Investment Research raised Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Wednesday, July 12th. ValuEngine raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. BidaskClub raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th.
Several large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in Adaptimmune Therapeutics PLC by 35.4% in the fourth quarter. Renaissance Technologies LLC now owns 445,100 shares of the biotechnology company’s stock valued at $1,803,000 after buying an additional 116,400 shares in the last quarter. Creative Planning raised its stake in Adaptimmune Therapeutics PLC by 32.8% in the first quarter. Creative Planning now owns 40,500 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 10,000 shares in the last quarter. Granite Investment Partners LLC purchased a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at about $1,078,000. Essex Investment Management Co. LLC purchased a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at about $225,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at about $120,000. 56.34% of the stock is currently owned by institutional investors and hedge funds.
Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded down 3.26% during mid-day trading on Friday, reaching $5.05. 172,564 shares of the company traded hands. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $8.36.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. The company had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. Equities research analysts predict that Adaptimmune Therapeutics PLC will post ($1.05) earnings per share for the current fiscal year.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.